Cancer doesn’t affect everyone the same way. Yet, minority populations — especially Black, Hispanic, Native American and Asian communities — are underrepresented in clinical trials.  Â
Currently, minority populations make up 21% of those on an active clinical trial at Mary Bird Perkins Cancer Center. In 2024, 18% of new clinical trial enrollments were from minority populations—well above national averages, which tend to be disproportionately less than their representation in the US population. These results can be attributed to Mary Bird Perkins’ prioritization of diversity in research and efforts to create more personalized and equitable opportunities.Â
Mary Bird Perkins Cancer Center is collaborating with The Walls Project, a local non-profit known for its transformational public art, to create a large-scale mural in North Baton Rouge that will amplify public understanding of clinical trials. The mural was unveiled in September 2025 and is intended to spark conversation and deepen public understanding of the importance of representation in clinical research. To learn more about the mural, located at the historic Cosey’s Barbershop at 1604 Plank Road, click here.Â
For many minority populations, clinical trials carry a legacy of mistrust rooted in historical injustices and unethical research practices. This understandable skepticism has led to underrepresentation in studies, which means treatments may not be as effective or well-understood across diverse communities.
Today, strict safeguards and ethical standards are in place to protect participants, and building trust through transparency and community engagement is essential. Increasing minority participation helps ensure that new cancer treatments are safe and effective for everyone.Â
For more information about clinical trials, visit marybird.org/research, email clinicalresearch@marybird.com or call (225) 215-1370.Â
